Isoliquiritigen enhances the antitumour activity and decreases the genotoxic effect of cyclophosphamide.

Hong Zhao,Xuan Yuan,Zhiping Wang,Xiling Sun,Defang Li,Qiusheng Zheng,Hongmei Chen,Jiangtao Jiang

doi:10.3390/molecules18088786

Abstract

The aim of this study was to evaluate the antitumour activities and genotoxic effects of isoliquiritigenin (ISL) combined with cyclophosphamide (CP) in vitro and in vivo. U14 cells were treated with either of ISL (5–25 μg/mL) or CP (0.25–1.25 mg/mL) alone or with combination of ISL (5–25 μg/mL) and CP (1.0 mg/mL) for 48 h. The proliferation inhibitory effect in vitro was evaluated by MTT and colony formation assays. KM mice bearing U14 mouse cervical cancer cells were used to estimate the antitumour activity in vivo. The genotoxic activity in bone marrow polychromatic erythrocytes was assayed by frequency of micronuclei. The DNA damage in peripheral white blood cells was assayed by single cell gel electrophoresis. The results showed that ISL enhanced antitumour activity of CP in vitro and in vivo, and decreased the micronucleus formation in polychromatic erythrocytes and DNA strand breaks in white blood cells in a dose-dependent way.

Highlights

Cancer is one of the major causes of mortality in humans throughout the World
The high rate of malignancy of these neoplasms is associated with rapid proliferation, numerous early metastases and high resistance to conventional treatments involving surgery, chemotherapy and radiation
The results from our lab showed that ISL was able to induce monocytic differentiation in HL-60 human leukemia cells [31,32] or B16F0 mouse melanoma cells [33], suppress proliferation and induce apoptosis in HeLa human cervical carcinoma cells [34,35] and SKOV-3 human ovarian carcinoma cells [36], we found that ISL and CP have synergistic action in inhibition of proliferation of U14 cells [37]

Summary

Introduction

Cancer is one of the major causes of mortality in humans throughout the World. According to a report dealing with the incidence and mortality of cancer in the World, about 12.7 million cancer cases and 7.6 million cancer deaths were estimated to have occurred in 2008; of these, 56% of the cases and64% of the deaths occurred in the economically developing world [1]. According to a report dealing with the incidence and mortality of cancer in the World, about 12.7 million cancer cases and 7.6 million cancer deaths were estimated to have occurred in 2008; of these, 56% of the cases and. It has been used to treat leukemia [4], breast cancer [5], small cell lung cancer [6], cervical cancer [7], non-Hodgkin’s lymphoma [8] and so on. It has severe and life-threatening adverse effects

Objectives

Results

Conclusion